Effect of resveratrol administration on ovarian morphology, determined by transvaginal ultrasound in patients with PCOS

Abstract Background High rate of anovulation in PCOS is associated with lack of development a dominant follicle. Intake of resveratrol has been associated with improved ovarian morphology in vitro and in animal PCOS model, but this finding has not been confirmed in randomized trials.Methods We randomly assigned 41 patients with PCOS, but without evidence of major medical disorders and who was not taking confounding medications including insulin sensitizers and steroids to received 1000 mg capsules containing resveratrol or matching placebo daily for up to 3 months. Transvaginal ultrasound examination was used to evaluate ovarian morphology.Results Resveratrol therapy, as compared with placebo, was associated with significantly higher rate of improvement in ovarian morphology (resveratrol group: 5 no polycystic ovarian morphology (PCOM), 8 bilateral and 6 unilateral and placebo group: 10 bilateral and 7 unilateral, (p= 0.02)). Women who received resveratrol had more dominant follicle than who received placebo with a significant reduction in ovarian volume (p0.05).Conclusions This study offered the novel therapeutic approach of resveratrol administration for PCOS women.